Sanofi in 250 million euro 'end-to-end' drug discovery deal using AI

9 May 2017

French pharma major Sanofi (Euronext: SAN) has signed a 250 million euro ($273 million) research collaboration and licence option agreement in metabolic disease with Exscientia, a UK company involved in artificial intelligence (AI)-driven drug discovery.

Exscientia will apply its unique platform to identify and validate combinations of drug targets that could work synergistically and be amenable to its bispecific-small-molecule design strategy.

"Sanofi has put together an excellent experimental backbone for this collaboration and we look forward to delivering high-value projects for the company"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical